Patents by Inventor Norbert Windhab
Norbert Windhab has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160151504Abstract: A method of penetrating a cell where the cell is contacted with a complex that includes (A) a peptide comprising at least 8 consecutive amino acids of the human lactoferrin protein or of the bovine lactoferrin protein; and (B) a cargo molecule bound to the peptide.Type: ApplicationFiled: December 1, 2015Publication date: June 2, 2016Applicant: Evonik Roehm GmbHInventors: Roland BROCK, Rainer Fischer, Mariola Fotin-Mleczek, Hansjoerg Hufnagel, Norbert Windhab
-
Publication number: 20150174088Abstract: Food supplement containing alpha-keto acids for supporting diabetes therapy. The present invention relates to a formulation which is used as food supplement and contains alpha-keto acids for supporting therapy in diabetes mellitus type II (DM).Type: ApplicationFiled: December 24, 2014Publication date: June 25, 2015Applicant: EVONIK DEGUSSA GMBHInventors: Andreas KARAU, Henrike GEBHARDT, Norbert WINDHAB, Matthias KOTTENHAHN, Yuefei LIU, Juergen M. STEINACKER
-
Patent number: 9050256Abstract: The invention relates to an oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles, wherein the dosage form has an at least two phase composition, wherein the phases can dissolve in the body after oral administration due to their formulation and the magnetizable particles are bound in formulation auxiliary substances and are present in a magnetized state, wherein the magnetized particles are present in at least two phases of the dosage form and generate magnetic fields, wherein these phases dissolve at different times in the body after oral administration, and wherein the magnetic field strength with respect to time, position and movement in the body is acquired using a detection system and can be evaluated using a computer-based evaluation system.Type: GrantFiled: August 30, 2010Date of Patent: June 9, 2015Assignee: Evonik Röhm GmbhInventors: Benedikt Hartwig, Norbert Windhab, Melanie Liefke, Juan Tome Alcalde, Michael Damm, Rosario Lizio, Michael Gottschalk, Angela Olf, Christian Meier, Andreas Gryczke
-
Publication number: 20150008914Abstract: The subject matter of the invention is a detector system for detecting magnetic bodies in the human organism, which comprises at least two sensor assemblies, wherein each sensor assembly has one, two or three anisotropic magnetic resistance sensors, of which the axes of weak magnetisation point in different directions in pairs, and each sensor assembly has a spacing of 0.5 to 50 cm from the sensor assembly or the other sensor assemblies, and at least two sensor assemblies are tilted at an angle of 0 to 45° with respect to one another, and in addition a method for detecting the magnetic flux produced by a magnetic body in the human organism, and the use of the detector system according to the invention for detecting swallowed magnetic bodies and the disintegration of the same in the digestive system.Type: ApplicationFiled: January 9, 2012Publication date: January 8, 2015Applicant: EVONIK ROEHM GMBHInventors: Benedikt Hartwig, Peter Niepoth, Steffen Junginger, Hans-Joachim Stiller, Norbert Windhab, Gerhard Geipel
-
Patent number: 8765152Abstract: The invention relates to a pharmaceutical or nutraceutical formulation comprising a core, comprising an active pharmaceutical or nutraceutical ingredient, a penetration promoter and a bioavailability promoting agent, and a polymeric coating for the gastrointestinal targeted release of the active ingredient, characterized in that the bioavailability promoting agent is a pharmaceutically acceptable inhibitor of proteolytic enzymes, which increases the oral bioavailability of the active ingredient by a factor of at least five, compared to a corresponding formulation without the bioavailability promoting agent.Type: GrantFiled: February 25, 2010Date of Patent: July 1, 2014Assignee: Evonik Roehm GmbHInventors: Rosario Lizio, Michael Gottschalk, Michael Damm, Norbert Windhab, Melanie Liefke, Guenter Schmitt, Erna Roth, Ruediger Alexowsky
-
Publication number: 20130302342Abstract: The invention refers to a human lactoferrin derived peptide for use as an antigen masking agent in the production of a pharmaceutical composition for delivery of a biological active substance in a mammalian organism, where the biological active substance is able to induce an undesired immune response by the mammalian organism, where the pharmaceutical composition comprises a supramolecular aggregate of the biological active substance and the human lactoferrin derived peptide, with the effect that after delivery of pharmaceutical composition to the mammalian organism, there is no or only a diminished induction of the undesired immune response against the biological active substance.Type: ApplicationFiled: November 26, 2010Publication date: November 14, 2013Applicant: Evonik Roehm GmbHInventors: Benedikt Hartwig, Juan Tome Alcalde, Norbert Windhab, María del Pilar Ansuategui Panzano, Matías Javier Vara Carrera
-
Publication number: 20130273163Abstract: The invention relates to novel particulate drug-delivery systems based on a polymer support containing at least one linear, branched or cross-linked polymer in a fraction of over 50 percent by weight in relation to the total weight of the support. The system is characterised in that at least one signal substance for transport through a biological barrier and at least one active ingredient are stored, the support, signal substance and active ingredient having no covalent links and no active-ingredient specific and signal substance specific coordinative links between one another.Type: ApplicationFiled: October 10, 2012Publication date: October 17, 2013Inventors: Matthias SEILER, Norbert Windhab, Manfred Stickler, Hans-Ulrich Petereit
-
Publication number: 20130108662Abstract: A peptide having an amino acid sequence containing at least eight consecutive amino acids of the human lactoferrin protein or of the bovine lactoferrin protein. The peptide is suitable as a cell-penetrating peptide. A complex of the peptide and a cargo molecule non-covalently bound to the peptide. The cargo molecule may be a nucleic acid, an amino acid, a peptide, a protein, a carbohydrate, a lipid, or a small molecule. A method of penetrating or transfecting a cell using the complex.Type: ApplicationFiled: July 25, 2012Publication date: May 2, 2013Applicant: Evonik Roehm GmbHInventors: Roland Brock, Rainer Fischer, Mariola Fotin-Mleczek, Hansjoerg Hufnagel, Norbert Windhab
-
Publication number: 20120315334Abstract: The invention relates to a pharmaceutical or nutraceutical formulation comprising a core, comprising an active pharmaceutical or nutraceutical ingredient, a penetration promoter and a bioavailability promoting agent, and a polymeric coating for the gastrointestinal targeted release of the active ingredient, characterized in that the bioavailability promoting agent is a pharmaceutically acceptable inhibitor of proteolytic enzymes, which increases the oral bioavailability of the active ingredient by a factor of at least five, compared to a corresponding formulation without the bioavailability promoting agent.Type: ApplicationFiled: February 25, 2010Publication date: December 13, 2012Applicant: Evonik Roehm GmbHInventors: Rosario Lizio, Michael Gottschalk, Michael Damm, Norbert Windhab, Melanie Liefke, Guenter Schmitt, Erna Roth, Ruediger Alexowsky
-
Patent number: 8313778Abstract: The invention relates to novel particulate drug-delivery systems based on a polymer support containing at least one linear, branched or cross-linked polymer in a fraction of over 50 percent by weight in relation to the total weight of the support. The system is characterized in that at least one signal substance for transport through a biological barrier and at least one active ingredient are stored, the support, signal substance and active ingredient having no covalent links and no active-ingredient specific and signal substance specific coordinative links between one another.Type: GrantFiled: October 25, 2006Date of Patent: November 20, 2012Assignee: Evonik Roehm GmbHInventors: Matthias Seiler, Norbert Windhab, Manfred Stickler, Hans-Ulrich Petereit
-
Publication number: 20120143039Abstract: The invention relates to an oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles, wherein the dosage form has an at least two phase composition, wherein the phases can dissolve in the body after oral administration due to their formulation and the magnetizable particles are bound in formulation auxiliary substances and are present in a magnetized state, wherein the magnetized particles are present in at least two phases of the dosage form and generate magnetic fields, wherein these phases dissolve at different times in the body after oral administration, and wherein the magnetic field strength with respect to time, position and movement in the body is acquired using a detection system and can be evaluated using a computer-based evaluation system.Type: ApplicationFiled: August 30, 2010Publication date: June 7, 2012Applicant: Evonik Roehm GmbHInventors: Benedikt Hartwig, Norbert Windhab, Melanie Liefke, Juan Tome Alcalde, Michael Damm, Rosario Lizio, Michael Gottschalk, Angela Olf, Christian Meier, Andreas Gryczke
-
Patent number: 8067581Abstract: Compounds relating to attachment chemistries for binding biomolecules to a substrate surface are described. These include compounds of the following structure: The biomolecule includes a single nucleic acid, oligonucleotides, polynucleotides, DNAs, RNAs, proteins, peptides, enzymes, antibodies, CNAs (cyclohexyl nucleic acids), p-MeNAs (methyl or methoxy phosphate nucleic acids), peptide nucleic acids (PNAs), and pyranosyl RNAs (p-RNAs).Type: GrantFiled: November 15, 2010Date of Patent: November 29, 2011Assignee: Sanofi-Aventis S.A.Inventors: Markus Schweitzer, Norbert Windhab, John R. Havens, Thomas J. Onofrey, Charles Greef, Daguang Wang
-
Publication number: 20110201080Abstract: Compounds relating to attachment chemistries for binding biomolecules to a substrate surface are described. These include compounds of the following structure: The biomolecule includes a single nucleic acid, oligonucleotides, polynucleotides, DNAs, RNAs, proteins, peptides, enzymes, antibodies, CNAs (cyclohexyl nucleic acids), p-MeNAs (methyl or methoxy phosphate nucleic acids), peptide nucleic acids (PNAs), and pyranosyl RNAs (p-RNAs).Type: ApplicationFiled: November 15, 2010Publication date: August 18, 2011Inventors: Markus Schweitzer, Norbert Windhab, John R. Havens, Thomas J. Onofrey, Charles Greef, Daguang Wang
-
Patent number: 7833715Abstract: Methods of binding biomolecules to a substrate are provided that include contacting the biomolecule with a branched linking moiety to form a branched linking structure. The branched linking structure is then contacted with a binding moiety on the substrate to form a coupled substrate binding structure, thereby binding the biomolecule to the substrate. The biomolecule may contain a Lewis base or a nucleophile to react with a Lewis acid or electrophile in the branched linking moiety. Alternatively, the biomolecule may contain a Lewis acid or electrophile that can react with a Lewis base or nucleophile in the branched linking moiety. Additionally, the biomolecule can be bound to the substrate through a covalent or non-covalent bond.Type: GrantFiled: January 18, 2007Date of Patent: November 16, 2010Assignee: Nanogen Recognomics GmbHInventors: Markus Schweitzer, Norbert Windhab, John R. Havens, Thomas J. Onofrey, Charles Greef, Daguang Wang
-
Publication number: 20100286377Abstract: Methods of binding biomolecules to a substrate are provided that include contacting the biomolecule with a branched linking moiety to form a branched linking structure. The branched linking structure is then contacted with a binding moiety on the substrate to form a coupled substrate binding structure, thereby binding the biomolecule to the substrate. The biomolecule may contain a Lewis base or a nucleophile to react with a Lewis acid or electrophile in the branched linking moiety. Alternatively, the biomolecule may contain a Lewis acid or electrophile that can react with a Lewis base or nucleophile in the branched linking moiety. Additionally, the biomolecule can be bound to the substrate through a covalent or non-covalent bond.Type: ApplicationFiled: January 18, 2007Publication date: November 11, 2010Inventors: Markus Schweitzer, Norbert Windhab, John R. Havens, Thomas J. Onofrey, Charles Greef, Daguang Wang
-
Publication number: 20100280123Abstract: Food supplement containing alpha-keto acids for supporting diabetes therapy. The present invention relates to a formulation which is used as food supplement and contains alpha-keto acids for supporting therapy in diabetes mellitus type II (DM).Type: ApplicationFiled: April 1, 2010Publication date: November 4, 2010Applicant: Evonik Degussa GmbHInventors: Andreas KARAU, Henrike Gebhardt, Norbert Windhab, Matthias Kottenhahn, Yuefei Liu, Jürgen M. Steinacker
-
Patent number: 7777024Abstract: The invention relates to a process for preparing a conjugate that includes a pentopyranosyl nucleic acid and a biomolecule. The process includes the steps of providing a pentopyranosyl nucleic acid having at least two pentopyranosyl nucleotide subunits that are covalently linked between carbon 4 and carbon 2 of their respective pentopyranosyl rings. The pentopyranosyl nucleic acid also has an electrophilic reactive group. A biomolecule having a nucleophilic reactive group is also provided. The electrophilic reactive group of the pentopyranosyl nucleic acid and the nucleophilic reactive group of the biomolecule are reacted to form a covalent bond.Type: GrantFiled: February 20, 2009Date of Patent: August 17, 2010Assignee: Aventis Research & Technologies GmbH & Co.Inventors: Christian Miculka, Norbert Windhab, Tilmann Brandstetter, Gerhard Burdinski
-
Patent number: 7700761Abstract: Provided are processes for preparing a 3?-deoxypentopyranosyl oligomers with linkers for linking biomolecules. The processes can the steps of: bonding a 4?-protected-3?-deoxypentopyranosyl nucleoside to a solid support by coupling the 2?-OH group with a CPG support or other similar support with an amide linkage; deprotecting the 4?-protected-3?-deoxypentopyranosyl nucleoside at the 4? position; deprotecting the 4?-protected-3?-deoxypentopyranosyl nucleoside at the 4? position; and conjugating a linker to the free 4? position. The resulting product can be conjugated via the linker to a biomolecule. The method can include, prior to addition of the linker, reacting the 4?-OH group of the 4?-protected-3?-deoxypentopyranosyl nucleoside that is linked to the solid support with a 4?-protected-3?-deoxypentopyranosyl nucleoside phosphoramidite in the presence of a coupling reagent, and oxidizing the reaction product. This step can be repeated one or more times to produce an oligomer of desired length.Type: GrantFiled: May 31, 2006Date of Patent: April 20, 2010Assignee: Nanogen Recognomics GmbHInventors: Christian Miculka, Thomas Wagner, Norbert Windhab
-
Publication number: 20100061932Abstract: The present invention is related to a peptide having an amino acid sequence comprising at least 8 consecutive amino acids of the human lactoferrin protein or of the bovine lactoferrin protein, whereby the peptide is suitable to act as a cell-penetrating peptide.Type: ApplicationFiled: October 25, 2006Publication date: March 11, 2010Applicant: Evonik Roehm GmbHInventors: Roland Brock, Rainer Fischer, Mariola Fotin-Mleczek, Hansjoerg Hufnagel, Norbert Windhab
-
Publication number: 20090221793Abstract: The invention relates to a process for preparing a conjugate that includes a pentopyranosyl nucleic acid and a biomolecule. The process includes the steps of providing a pentopyranosyl nucleic acid having at least two pentopyranosyl nucleotide subunits that are covalently linked between carbon 4 and carbon 2 of their respective pentopyranosyl rings. The pentopyranosyl nucleic acid also has an electrophilic reactive group. A biomolecule having a nucleophilic reactive group is also provided. The electrophilic reactive group of the pentopyranosyl nucleic acid and the nucleophilic reactive group of the biomolecule are reacted to form a covalent bond.Type: ApplicationFiled: February 20, 2009Publication date: September 3, 2009Inventors: Christian Miculka, Norbert Windhab, Tilmann Brandstetter, Gerhard Burdinski